Change Emphasizes Lumendi’s Vision to Transform the GI Landscape from Surgical to Endolumenal
WESTPORT, CONNECTICUT, August 12, 2020 — Connecticut-based medical device innovator Lumendi, LLC has announced a change in the company’s Mission & Vision statements to better communicate the intended path of its innovative DiLumenTM Endolumenal Interventional Platform (EIP) to transform the GI landscape from surgical intervention to endolumenal. The new statement, Pioneering Endosurgery, will also be used as its tagline in print, web and social media communications.
Since it was founded in 2014, Lumendi has been dedicated to improving healthcare through the development and application of medical technology that enables clinicians to perform existing endolumenal procedures more efficiently. By reducing procedure time, positively impacting recovery rates and outcomes, and decreasing costs to the healthcare system, Lumendi is expanding options for incisionless therapies to treat conditions that previously required abdominal surgery.
Pioneering Endosurgery reflects Lumendi’s innovative, three-part pathway to:
- expand indication areas and procedures in the upper gastrointestinal tract, which includes a recent submission to the FDA;
- innovate improvements planned for the DiLumen EIP, including a proprietary lubricated inner surface of DiLumen’s sheath for better endoscope handling performance; and
- commercially release the DiLumen C2 platform to bring robotic-like end-effectors to endolumenal surgery in a low-cost, disposable format to provide endoscopists with unprecedented control of tissue.
First Endoscopic Appendectomy In June 2020, Lumendi reported the first endoscopic appendectomy using its DiLumen EIP after a patient in Baltimore, Maryland underwent a purely endoscopic endolumenal appendectomy to remove a lesion previously identified at the appendiceal orifice. The patient reported no post-procedure pain, was discharged home from the endoscopy unit, resumed regular physical exercises, and returned to work the morning after the appendectomy.
“This new positioning reflects our commitment to develop and expand our DiLumen platform beyond current FDA-cleared devices approved for complex polypectomies. We expect to file several new applications associated with our DiLumen endolumenal interventional platform for regulatory clearance within the next 12 months,” said Dr. Peter Johann, Founder, Chairman & CEO of Lumendi. “Future devices will continue to help prevent colectomies while enabling new therapeutic interventions in the lower and upper GI tract. We continue to collaborate with recognized global thought leaders in the GI and surgical fields to facilitate the design, development, and application of Lumendi’s expanded platforms.”
 The DiLumen C2 is the second-generation endoscopic accessory indicated to ensure complete positioning of an endoscope in the large intestine and assist with optical visualization, diagnosis and endoscopic treatment.